Please provide your email address to receive an email when new articles are posted on . The FDA approved ustekinumab for pediatric patients with moderate to severe ulcerative colitis. The ...

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. Ulcerative colitis may cause ...

Ulcerative colitis has been linked to an imbalanced gut microbiome and decreased intestinal barrier. Your age, gender, and family history can affect your risk of ulcerative colitis. Certain ...

Treatment with investigational duvakitug appeared to improve remission rates among patients with ulcerative colitis and endoscopic response rates in those with Crohn's disease in a phase IIb study.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted other treatment options, according to findings from two new trials. “These ...

Among patients with ulcerative colitis (UC), initiation of biologic therapy within 12 months of diagnosis was associated with a significantly reduced risk for disease progression, with no proximal ...

Ulcerative colitis (UC) is one of the most common inflammatory bowel diseases, a lifelong condition that can cause chronic inflammation and ulcers in the lining of the large intestine. This can lead ...

Share on Pinterest Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...